Century Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
118
- Stock Symbol
-
IPSC
- Investments
-
2
- Share Price
-
$1.65
- (As of Friday Closing)
Century Therapeutics General Information
Description
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Contact Information
Website
www.centurytx.comCorporate Office
- 25 North 38th Street
- 11th Floor
- Philadelphia, PA 19104
- United States
Corporate Office
- 25 North 38th Street
- 11th Floor
- Philadelphia, PA 19104
- United States
Century Therapeutics Timeline
Century Therapeutics Stock Performance
As of 13-Nov-2026, Century Therapeutics’s stock price is $1.65. Its current market cap is $300M with 182M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.65 | $1.63 | $0.43 - $3.04 | $300M | 182M | 716K | -$0.64 |
Century Therapeutics Financials Summary
As of 30-Sep-2026, Century Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 228,593 | (841) | (57,637) | 76,722 |
| Revenue | 0 | 109,164 | 6,589 | 2,235 |
| EBITDA | (94,596) | (3,893) | (124,479) | (133,885) |
| Net Income | (98,819) | (9,580) | (126,566) | (136,673) |
| Total Assets | 262,626 | 223,704 | 353,216 | 360,691 |
| Total Debt | 37,492 | 43,565 | 53,830 | 48,171 |
Century Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Century Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Century Therapeutics Comparisons
Industry
Financing
Details
Century Therapeutics Competitors (73)
One of Century Therapeutics’s 73 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA |
Century Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Century Therapeutics Patents
Century Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026128475-A1 | Genetically engineered induced pluripotent stem cells and effector cells derived therefrom | Pending | 09-Dec-2024 | ||
| WO-2026128487-A1 | Methods for generating αβ t cells and related compositions | Pending | 09-Dec-2024 | ||
| WO-2026122928-A2 | Genetically engineered cells having chimeric antigen receptors with cd30 endodomains, and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2026122928-A3 | Genetically engineered cells having chimeric antigen receptors with cd30 endodomains, and uses thereof | Pending | 06-Dec-2024 | ||
| WO-2025207798-A1 | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof | Pending | 26-Mar-2024 | C07K16/2866 |
Century Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Century Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Century Therapeutics Acquisitions (2)
Century Therapeutics’s most recent deal was a Merger/Acquisition with Clade Therapeutics for . The deal was made on 11-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Clade Therapeutics | 11-Apr-2024 | Merger/Acquisition | Drug Discovery | ||
| Empirica Therapeutics | 23-Jun-2020 | Merger/Acquisition | Drug Discovery |
Century Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.35 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Century Therapeutics FAQs
-
When was Century Therapeutics founded?
Century Therapeutics was founded in 2018.
-
Where is Century Therapeutics headquartered?
Century Therapeutics is headquartered in Philadelphia, PA.
-
What is the size of Century Therapeutics?
Century Therapeutics has 118 total employees.
-
What industry is Century Therapeutics in?
Century Therapeutics’s primary industry is Drug Discovery.
-
Is Century Therapeutics a private or public company?
Century Therapeutics is a Public company.
-
What is Century Therapeutics’s stock symbol?
The ticker symbol for Century Therapeutics is IPSC.
-
What is the current stock price of Century Therapeutics?
As of 13-Nov-2026 the stock price of Century Therapeutics is $1.65.
-
What is the current market cap of Century Therapeutics?
The current market capitalization of Century Therapeutics is $300M.
-
Who are Century Therapeutics’s competitors?
Fate Therapeutics, Lyell Immunopharma, Caribou Biosciences, Allogene Therapeutics, and Carisma Therapeutics are some of the 73 competitors of Century Therapeutics.
-
What is Century Therapeutics’s annual earnings per share (EPS)?
Century Therapeutics’s EPS for 12 months was -$0.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
